13 results on '"Jara, LJ"'
Search Results
2. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand?
- Author
-
Jara LJ, Vera-Lastra O, Mahroum N, Pineda C, and Shoenfeld Y
- Subjects
- COVID-19 Vaccines adverse effects, Humans, SARS-CoV-2, Syndrome, Vaccination adverse effects, COVID-19, Vaccines
- Abstract
To date, around 60% of the world population has been protected by vaccines against SARS-CoV-2, significantly reducing the devastating effect of the pandemic and restoring social economic activity through mass vaccination. Multiple studies have demonstrated the effectiveness and safety of vaccines against COVID-19 in healthy populations, in people with risk factors, in people with or without SARS-CoV-2 infection, and in immunocompromised people. According to the criteria for post-vaccine adverse events established by the World Health Organization, a minority of individuals may develop adverse events, including autoimmune syndromes. The exact mechanisms for the development of these autoimmune syndromes are under study, and to date, a cause-effect relationship has not been established. Many of these autoimmune syndromes meet sufficient criteria for the diagnosis of Adjuvant-Induced Autoimmune Syndrome (ASIA syndrome). The descriptions of these autoimmune syndromes open new perspectives to the knowledge of the complex relationship between the host, its immune system, with the new vaccines and the development of new-onset autoimmune syndromes. Fortunately, most of these autoimmune syndromes are easily controlled with steroids and other immunomodulatory medications and are short-lived. Rheumatologists must be alert to the development of these autoimmune syndromes, and investigate the relationship between autoimmune/inflammatory symptoms and vaccination time, and assess their therapeutic response., (© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).)
- Published
- 2022
- Full Text
- View/download PDF
3. Primary antiphospholipid syndrome, Addison disease, and adrenal incidentaloma.
- Author
-
Medina G, Jiménez-Arellano MP, Muñoz-Solís A, Servín-Torres E, Ramírez-Mendoza P, and Jara LJ
- Subjects
- Adrenal Gland Neoplasms diagnosis, Adrenal Gland Neoplasms etiology, Adrenal Insufficiency diagnosis, Adrenal Insufficiency etiology, Antibodies, Antiphospholipid blood, Humans, Male, Young Adult, Addison Disease immunology, Adrenal Gland Neoplasms immunology, Adrenal Insufficiency immunology, Antiphospholipid Syndrome complications
- Abstract
Primary adrenal failure comprises an insufficient production of mineralocorticoids and glucocorticoids in the adrenal cortex. A rare manifestation of antiphospholipid syndrome (APS) is adrenal failure. The majority of patients with adrenal involvement in APS develop an irreversible cortisol deficiency and atrophy of the adrenal glands. Adrenal incidentalomas are adrenal masses larger than 1 cm that are discovered in the course of diagnostic evaluation or treatment for another medical condition. Its prevalence is calculated in 1.5-9% of individuals. We describe an exceptional case of a 23-year-old male patient with APS with persistent high levels of antiphospholipid antibodies (aPL) from the time of diagnosis, who developed Addison's disease as a manifestation of APS with atrophy of the adrenal glands, in whom an adrenal incidentaloma was developed later and was corroborated as an aldosterone-producing adenoma. Currently, the patient is asymptomatic and without manifestations of tumor recurrence. The protumoral effect of elevated and persistent aPL is discussed.
- Published
- 2020
- Full Text
- View/download PDF
4. Myocardial function in primary antiphospholipid syndrome using speckle-tracking echocardiography.
- Author
-
Medina G, Gómez-Bañuelos E, Calderón-Aranda E, Cruz-Domínguez MP, Vera-Lastra O, and Jara LJ
- Subjects
- Adult, Aged, Case-Control Studies, Disease Progression, Female, Heart diagnostic imaging, Heart physiopathology, Heart Ventricles diagnostic imaging, Humans, Inflammation, Male, Middle Aged, Reproducibility of Results, Ventricular Function, Left, Antiphospholipid Syndrome diagnostic imaging, Antiphospholipid Syndrome physiopathology, Echocardiography methods, Myocardium pathology, Obesity complications
- Abstract
Antiphospholipid syndrome (APS) patients have high cardiovascular risk. Speckle-tracking echocardiography (STE) detects myocardial function. To evaluate the myocardial function in primary APS (PAPS) patients using two-dimensional echocardiography (2-D) obtaining values of left ventricle global longitudinal strain (GLS) by STE. Patients with PAPS, > 16 years, both genders, without signs and symptoms of heart disease were recruited and matched with healthy controls by age and gender. Demographic, clinical data, and cardiovascular risk factors were recorded. Images from the two-, three-, and four-chamber views were recorded and analyzed with STE and values of GLS. Descriptive and analytic statistics were applied. Thirty-eight PAPS patients and 21 controls were included. Age 46.7 ± 10, disease evolution 13.06 ± 6.69 years. Obesity and dyslipidemia were more frequent in PAPS patients in comparison with controls. Even though the proportion of obesity was greater in PAPS patients than in the control group, we did not find significant differences, neither in patients with/without metabolic syndrome. Regarding patients with and without obesity with lower GLS values, there were no differences either. Average GLS was lower in PAPS than in controls. Segments and myocardial regions showed lower values of myocardial deformation in PAPS patients than controls, including apical segments suggesting underlying heart disease. GLS is reduced in PAPS compared with healthy subjects. STE is a suitable method to detect cardiac affection in patients without apparent cardiac involvement. Studies with this technique to monitor progression of heart disease in PAPS are necessary.
- Published
- 2018
- Full Text
- View/download PDF
5. Autoimmune/inflammatory syndrome induced by mineral oil: a health problem.
- Author
-
Vera-Lastra O, Medina G, Cruz-Domínguez MP, Ramírez GM, Blancas RBP, Amaro ALP, Martínez AV, Delgado JS, and Jara LJ
- Subjects
- Animals, Autoimmune Diseases diagnosis, Autoimmune Diseases therapy, Humans, Autoimmune Diseases chemically induced, Cosmetic Techniques adverse effects, Mineral Oil adverse effects
- Abstract
Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) includes the following conditions: siliconosis, Gulf War syndrome, macrophagic myofasciitis syndrome, and post-vaccination phenomena. Afterward, other syndromes have been recognized, such as in ASIA by mineral oil (ASIA-MO). These conditions are triggered by adjuvants and they are the result of the interplay of genetic and environmental factors. ASIA-MO is defined as the infiltration of oily type modeling substances for cosmetic purposes. It has been reported in many countries and used surreptitiously. Pathogenesis of ASIA-MO is not clear, but is characterized by chronic granulomatous inflammation, like the pristane model in mice, with increase of proinflammatory cytokines: type I interferons (IFNα and IFNß), systemic lupus erythematosus (SLE), and erosive arthritis. In humans, an increase of interleukin 1 (IL-1) has been found. Clinical spectrum of ASIA-MO is heterogeneous, varying from mild to severe and being local and systemic. The systemic manifestations can be non-specific and specific, meeting criteria for any autoimmune disease (AID), i.e., SLE, rheumatoid arthritis, and systemic sclerosis, among others. The areas of the body where the mineral oil is mostly applied include the following: buttocks (38-72%), breasts (12-16%), lower extremities (18-22%), and face (6-10%). The penis augmentation is also common. Treatment is focused on local and systemic manifestations and requires medical and surgical management representing a challenge for the physician.
- Published
- 2018
- Full Text
- View/download PDF
6. Splenectomy in systemic lupus erythematosus and autoimmune hematologic disease: a comparative analysis.
- Author
-
Barron N, Arenas-Osuna J, Medina G, Cruz-Dominguez MP, González-Romero F, Velásques-García JA, Ayala-López EA, and Jara LJ
- Subjects
- Adult, Anemia, Hemolytic, Autoimmune complications, Female, Humans, Laparoscopy methods, Lupus Erythematosus, Systemic complications, Male, Purpura, Thrombocytopenic, Idiopathic complications, Treatment Outcome, Anemia, Hemolytic, Autoimmune surgery, Lupus Erythematosus, Systemic surgery, Purpura, Thrombocytopenic, Idiopathic surgery, Splenectomy methods
- Abstract
The objective of the study is to analyze the efficacy and safety of splenectomy in the management of refractory autoimmune thrombocytopenia (AT)/autoimmune hemolytic anemia (AIHA) associated or not with systemic lupus erythematosus. Thirty-four patients after splenectomy due to severe AT and/or AIHA were divided into group 1 (G1) 18 SLE/APS patients: 9 AT/SLE patients, 6 SLE/antiphospholipid syndrome (APS), and 3 primary APS. Group 2 (G2): 16 patients without SLE/APS: 2 Fisher-Evans syndrome and 14 AIHA. Surgery approach when (1) platelets ≤ 50,000/ml despite 2 weeks on medical therapy, (2) medically dependent, and (3) medically intolerant or after two hemolytic crises in AIHA patients. Splenectomy response: (1) complete (CR): ≥ 150,000 platelets/ml, (2) partial: 50,000-149,000/ml, or (3) none: ≤ 50,000/ml. CR for AIHA: hemoglobin ≥9 g/dl., Statistical Analysis: descriptive statistics and chi-square test. The mean age was 34.6 years; mean follow-up: 28.5 months. Open splenectomy in 15/34 vs laparoscopy in 19/34 (p = NS). CR in 15/34, G1: 4/18, G2: 11/16, (p = 0.006). Complications in 6/34, 5 from G2 vs 1 from G1 (p = 0.05). Relapse in 7/18 patients in G1 and 3/16 in G2 (p = 0.05). Open and laparoscopic splenectomies in SLE and AT patients are as effective as in those without SLE; however, patients with SLE and APS had more relapses.
- Published
- 2018
- Full Text
- View/download PDF
7. Inflammatory biomarkers, disease activity index, and self-reported disability may be predictors of chronic arthritis after chikungunya infection: brief report.
- Author
-
Sepúlveda-Delgado J, Vera-Lastra OL, Trujillo-Murillo K, Canseco-Ávila LM, Sánchez-González RA, Gómez-Cruz O, Lugo-Trampe A, Fernández-Salas I, Danis-Lozano R, Contreras-Contreras A, Mendoza-Torres A, Domínguez-Arrevillaga S, Mena-Vela BA, Ocaña-Sibilla M, Ramirez-Valdespino JC, and Jara LJ
- Subjects
- Adult, Aged, Arthritis blood, Arthritis diagnosis, Biomarkers blood, Chikungunya Fever blood, Female, Humans, Male, Middle Aged, Prospective Studies, Self Report, Severity of Illness Index, Arthritis etiology, C-Reactive Protein metabolism, Chikungunya Fever complications, Inflammation blood, Rheumatoid Factor blood
- Abstract
The chikungunya virus (ChikV) is a reemerging mosquito-borne pathogen that causes disabling chronic arthritis. The relationship between clinical evolution and inflammatory biomarkers in patients with ChikV-induced arthritis has not been fully described. We performed a prospective case series to evaluate the association among joint involvement, self-reported disability, and inflammatory biomarkers. Patients with ChikV infection were followed for 1 year. Joint involvement and self-reported disability were evaluated with disease activity index 28 (DAS-28) and World Health Organization Disablement Assessment Schedule II (WHODAS-II). Interleukin-6 (IL-6), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) were used as biomarkers. Ten patients with mean age 48 ±15.04 years were included. Symptoms at diagnosis were fever, arthralgias, myalgias, rash, arthritis, nausea, vomiting, and back pain. Polyarticular involvement was present in seven cases. At diagnosis, measures were as follows: DAS-28, 5.08±1.11; WHODAS-II score, 72.3±10.3 %; CRP, 5.09±7.23 mg/dL; ESR, 33.5±17.5 mm/h; RF, 64±21.7 IU/mL; and IL-6, 17.6±10.3 pg/mL. Six patients developed subacute and chronic symptoms. During follow-up, DAS-28 index, WHODAS-II score, ESR, and IL-6 were statistically different in patients with subacute and chronic symptoms compared to those who resolved in the acute phase (p < 0.05). DAS-28 index, WHODAS-II score, and IL-6 were related to chronicity of articular symptoms and could be used as predictors of ChikV-induced arthritis.
- Published
- 2017
- Full Text
- View/download PDF
8. Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis.
- Author
-
Cruz-Domínguez MP, García-Collinot G, Saavedra MA, Medina G, Carranza-Muleiro RA, Vera-Lastra OL, and Jara LJ
- Subjects
- Adult, Antibodies, Antinuclear blood, Calcinosis complications, Calcinosis ethnology, Calcium blood, Female, Hep G2 Cells, Humans, Male, Mexico, Middle Aged, Multivariate Analysis, Parathyroid Hormone blood, Phosphorus blood, Prevalence, Prospective Studies, Scleroderma, Systemic complications, Scleroderma, Systemic ethnology, Vitamin D blood, Calcinosis blood, Calcinosis diagnostic imaging, Scleroderma, Systemic blood, Scleroderma, Systemic diagnostic imaging
- Abstract
Calcinosis is a frequent complication of systemic sclerosis (SSc) that is usually located in extremities but may occur across the board. The aim of our study was to identify and quantify the distribution of calcinosis in a cohort of Mexican patients with SSc and its association with clinical features and autoantibodies. A cohort of patients with SSc (2013 ACR/EULAR criteria), classified in diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) (Le Roy criteria), was studied. For their analysis, patients were allocated into those with and without calcinosis (clinical and/or radiological). The evaluation included the modified Rodnan scale for skin and Medsger disease severity scale (DSS). Calcium, phosphorus, vitamin D, and parathyroid hormone (PTH) and antinuclear antibodies and extractable nuclear antigens were determined in serum. A total of 109 patients were included, 41 (37 %) with and 68 (63 %) without calcinosis. Calcinosis was more frequent in patients with dcSSc (55 vs 27 %). In total, we identified 354 sites with calcinosis and mean per patient of 12.0 ± 9.1; the most common sites affected were the hands (83 %), proximal upper extremity (27 %), and proximal lower extremity (22 %). Patients with calcinosis had a higher score of Rodnan scale, Mesdger DSS, and frequency of anti-nucleolar and anti-Scl-70 antibodies compared to those without calcinosis. Abnormal PTH elevation was found in 35 % of patients with calcinosis and 23 % without it. The prevalence of calcinosis is high in Mexican patients with SSc, especially in diffuse variety, and is associated with increased severity of disease.
- Published
- 2017
- Full Text
- View/download PDF
9. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome.
- Author
-
Saavedra MÁ, Sánchez A, Morales S, Ángeles U, and Jara LJ
- Subjects
- Abortion, Spontaneous, Adult, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Infant, Newborn, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic immunology, Maternal Exposure, Multivariate Analysis, Patient Safety, Pregnancy, Pregnancy Complications drug therapy, Pregnancy Outcome, Premature Birth, Young Adult, Azathioprine adverse effects, Azathioprine therapeutic use, Lupus Erythematosus, Systemic drug therapy
- Abstract
The objective of this study was to evaluate the risk of adverse fetal outcome in systemic lupus erythematosus (SLE) women exposed to azathioprine during pregnancy. We reviewed the medical records of SLE pregnant women followed from January 2005 to April 2013. The patients were evaluated at least once in each trimester and postpartum. Relevant fetal outcomes were extracted, such as rate of liveborns, fetal loss (spontaneous abortion and stillbirth), term delivery, preterm birth, neonatal death, low birth weight, low birth weight at term, and congenital malformations. A detailed history of drug use during pregnancy was obtained. We studied 178 pregnancies (in 172 women), 87 of them were exposed to azathioprine (AZA-group) and the remaining 91 were not exposed (NO AZA-group). Exposure to other drugs was similar in both groups. The rate of live births, spontaneous abortions mean birth weight, weeks of gestation, rate of birth weight <2500 g, and low birth weight at term did not differ between groups. No infant had major congenital abnormalities. Multivariate analysis showed that preeclampsia, premature rupture of membranes (PROM), lupus flare, and anti-DNA positive were associated with an increased risk of poor fetal outcome. Our study suggests that the use of azathioprine is safe and lacks of teratogenity in patients with SLE and pregnancy. Exposure to azathioprine during pregnancy is not associated with poor fetal outcome.
- Published
- 2015
- Full Text
- View/download PDF
10. Primary and secondary central nervous system vasculitis: clinical manifestations, laboratory findings, neuroimaging, and treatment analysis.
- Author
-
Vera-Lastra O, Sepúlveda-Delgado J, Cruz-Domínguez Mdel P, Medina G, Casarrubias-Ramírez M, Molina-Carrión LE, Pineda-Galindo LF, Olvera-Acevedo A, Hernández-Gonzalez C, and Jara LJ
- Subjects
- Adult, Biopsy, Cerebral Angiography, Cyclophosphamide administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Headache, Humans, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Methylprednisolone administration & dosage, Middle Aged, Neuroimaging, Prednisone administration & dosage, Recurrence, Vasculitis diagnosis, Vasculitis, Central Nervous System diagnosis
- Abstract
The objectives of this study are to compare the initial clinical, laboratory, and imaging features in primary central nervous system vasculitis (PCNSV) vs secondary central nervous system vasculitis (SCNSV) and follow up after treatment with intravenous cyclophosphamide (IV-CYC) plus glucocorticosteroids (GCS): methylprednisolone (MP). Neurological, laboratory, and neuroimaging findings were analyzed in PCNSV and SCNSV patients. Cerebral biopsy (CB) was performed in nine patients. Both groups received at onset MP plus IV-CYC for 6 months, followed by bimonthly IV-CYC plus prednisone (PND) for 12 months. All patients were followed during 36 months. Thirty patients were included (12 PCNSV and 18 SCNSV). Focal and non-focal neurological manifestations were similar in both groups, headache being the most frequent manifestation in both groups. Fatigue, myalgias, arthralgias, neuropathy, low leukocytes and platelets, elevated erythrocyte sedimentation rate, positive antinuclear antibodies (ANA), anti-double-stranded DNA (dsDNA), antineutrophil cytoplasmic antibodies (ANCA), low complement, and rheumatoid factor were more frequent in SCNSV (p < 0.05). In cerebrospinal fluid, pleocytosis and proteins were higher in PCNSV (p < 0.05). Periventricular and subcortical hyperintense lesions were observed in cranial magnetic resonance imaging in both vasculitides. Cerebral angiography and angioresonance showed narrowing of vasculature in all patients in both groups. CB showed gliosis and lymphocytic infiltration within and around the walls in four patients and granulomatous infiltration in the other patients. After treatment, the Kaplan-Meier survival curve showed a higher relapse-free survival in PCNSV (p < 0.05). Neurological manifestations and neuroimaging findings were similar in both groups of vasculitides, but general symptoms, joint, musculoskeletal, and peripheral neuropathy were preponderant in SCNSV. After treatment with IV-CYC and GCS, patients with PCNSV had a higher relapse-free survival than those with SCNSV.
- Published
- 2015
- Full Text
- View/download PDF
11. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy.
- Author
-
Saavedra MA, Cruz-Reyes C, Vera-Lastra O, Romero GT, Cruz-Cruz P, Arias-Flores R, and Jara LJ
- Subjects
- Adult, Antimalarials therapeutic use, Azathioprine therapeutic use, Comorbidity, Drug Therapy, Combination, Female, Fetal Diseases diagnosis, Humans, Immunosuppressive Agents therapeutic use, Lupus Nephritis drug therapy, Mexico epidemiology, Multivariate Analysis, Prednisone therapeutic use, Pregnancy, Prognosis, Fetal Diseases epidemiology, Lupus Nephritis epidemiology, Pregnancy Complications epidemiology, Pregnancy Outcome
- Abstract
Previous reports suggest that renal involvement before pregnancy or active renal disease during pregnancy may be associated with poor fetal and maternal outcomes in systemic lupus erythematosus (SLE) women. We report our experience of fetal and maternal complications in pregnant lupus women with and without previous lupus nephritis. We analyzed the clinical records of pregnant SLE patients attended in a tertiary reference center during a 5-year period. Patients were allocated into two groups according to the presence or absence of previous lupus nephritis. Women were evaluated monthly during pregnancy and at least 1 month postpartum. Maternal and fetal outcomes of pregnancy were abstracted. We included 95 pregnancies in 92 patients. Compared with pregnant women without lupus nephritis (n = 60), pregnancies with previous lupus nephritis (n = 35) were associated with a higher risk of maternal complications (88.5% vs. 43.3%, p = 0.00001), higher rate of lupus flares (54.2% vs. 25%, p = 0.004), and renal flares (45.7% vs. 6.6%, p = 0.00001), but most of which in most instances were reversible. On the other hand, fetal outcome was similar in both groups. Multivariate analysis showed that previous lupus nephritis and active lupus at conception were predictors of adverse maternal outcome. Pregnancies in women with previous lupus nephritis had a higher rate of maternal complications in comparison with those without. However, fetal prognosis was similar in both groups.
- Published
- 2012
- Full Text
- View/download PDF
12. Thyroid disease in Sjögren's syndrome.
- Author
-
Jara LJ, Navarro C, Brito-Zerón Mdel P, García-Carrasco M, Escárcega RO, and Ramos-Casals M
- Subjects
- Autoimmune Diseases diagnosis, Autoimmune Diseases metabolism, Female, Humans, Lymphoma, B-Cell, Marginal Zone complications, Lymphoma, B-Cell, Marginal Zone diagnosis, Male, Prevalence, Sjogren's Syndrome epidemiology, Thyroid Diseases epidemiology, Thyroiditis, Autoimmune, Time Factors, Sjogren's Syndrome complications, Sjogren's Syndrome diagnosis, Thyroid Diseases complications
- Abstract
From 1960 to 2007, an important number of patients with primary Sjögren's syndrome (pSS) along with thyroid disease diagnosed by laboratory data and clinical presentation were reported. The most common thyroid disorder found was autoimmune thyroiditis and the most common hormonal pattern was subclinical hypothyroidism. The coexistence of SS and thyroiditis is frequent and suggests a common genetic or environmental factor predisposition with similar pathogenic mechanisms. pSS was ten times more frequent in patients with autoimmune thyroid disease and autoimmune thyroiditis was nine times more frequent in pSS. Therefore, SS should be studied in patients with thyroid disease and vice versa. Antigens are shared by both thyroid and salivary glands, which could be responsible for the association between both diseases. Immunogenetic studies had suggested that both diseases have a common genetic predisposition. pSS and thyroid disease patients were mostly women with positive antithyroglobulin, antiparietal cell and antithyroid peroxidase antibodies. Thyroid dysfunction is frequent in pSS patients and those prone to develop thyroid disorders are identified by thyroid-related autoantibodies or by rheumatoid factor and anti-Ro/SSA activity. Patients with pSS have an increased tendency to develop other autoimmune diseases. Hypothyroidism was the most common autoimmune disease developed in pSS patients during follow-up of 10.5 years. Lymphomas are also associated with SS and thyroiditis and a 67-fold increased risk for thyroid mucosa-associated lymphoid tissue (MALT) lymphoma and a 44-fold increased risk for parotid lymphoma is being attributed to autoimmune thyroiditis and pSS. It is suggested that immune mechanism deficiency is a causal factor for B cell lymphoma in pSS and autoimmune thyroid disease. Other studies are necessary to clarify the shared pathogenesis mechanism in SS and autoimmune thyroid disease and to understand this fascinating autoimmune association.
- Published
- 2007
- Full Text
- View/download PDF
13. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus.
- Author
-
Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, and Espinoza LR
- Subjects
- Central Nervous System Diseases blood, Central Nervous System Diseases cerebrospinal fluid, Enzyme-Linked Immunosorbent Assay, Female, Humans, Interleukin-6 blood, Interleukin-6 cerebrospinal fluid, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic cerebrospinal fluid, Prolactin blood, Prolactin cerebrospinal fluid, Prospective Studies, Radioimmunoassay, Central Nervous System Diseases metabolism, Interleukin-6 metabolism, Lupus Erythematosus, Systemic metabolism, Prolactin metabolism
- Abstract
We investigated the levels of prolactin (PRL) and interleukin-6 (IL-6) in the cerebrospinal fluid (CSF) and serum of systemic lupus erythematosus patients with central nervous system involvement (CNS-SLE), and examined whether PRL and IL-6 have a relationship. Serum and CSF PRL and IL-6 were measured in the following groups of patients and controls: group I: seven patients with CNS-SLE; group II: three SLE patients without CNS involvement (non CNS-SLE); group III: 10 patients with neurocysticercosis; and group IV: six healthy women. The patients were clinically assessed. CSF PRL and IL-6 were elevated in group I (CNS-SLE) in comparison with all other groups (p<0.001). In addition, four of seven patients had higher levels of IL-6 and PRL in CSF than in serum. A positive correlation between PRL and IL-6 in CSF of SLE was observed (r=0.88, p<0.001). The mean serum PRL concentrations were not significantly different in all groups, but high levels of IL-6 were found in the serum of group I in comparison with groups II and IV (p<0.001). The serum levels of group III were not different from those of group I. These results demonstrate the presence of intrathecal synthesis and elevations of CSF PRL and IL-6 in active CNS-SLE involvement and indicate that measurements of CSF PRL and IL-6 may be useful in the evaluation of neuropsychiatric lupus erythematosus.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.